Linkedin Facebook Twitter Youtube

22 Jul PolTREG

Posted at 20:08h in by

Daniel Shelly, Ph.D., Chief Business Development Officer

Oct. 7 | 11:45am | FLW Ballroom G

Gdansk Poland

(NASDAQ: PTG)

Poltreg SA and its wholly owned Subsidiary, Immuthera, are pioneers in T-Regulatory cell therapy (Tregs). PolTREG is a fully integrated clinical stage company with extensive clinical experience with Tregs, a pipeline of advanced (modified, engineered, and Allogeneic) Treg and mRNA immunotherapies, and commercial stage cGMP cell manufacturing. Immuthera has recently launched in the US and will be bringing Treg cell therapies and other technologies licensed from PolTREG, into the US, starting with our Presymptomatic (Stage 1 & 2) T1D study (primarily in children as young as 6) and Progressive MS. We will follow with our CAR-Treg for ALS and MS and our mRNA immuno therapy for T1D.

www.poltreg.com



About the Event

The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering capabilities, exclusive networking opportunities, and 110+ dedicated presentations by the leading publicly traded and privately held companies in the space. Attracting over 1,500 attendees – over 30% of which are C-level executives – this conference enables key partnerships through more than 5,000 one-on-one meetings while highlighting the significant clinical and commercial progress in the field.

Dates & Location

October 5-7, 2026
Arizona Biltmore
Phoenix, AZ

Program Organizer

By using this website you agree to accept our Privacy Policy and Terms & Conditions